The size of the Radiotherapy Market in the Asia Pacific was worth USD 1.37 billion in 2021 and is estimated to be growing at a CAGR of 6.82% to reach USD 1.90 billion by 2026.
The Asia-pacific radiotherapy market is expected to observe the highest growth rate during the forecast period owing to several factors comprising refining healthcare infrastructure and supportive government activities.
In the present global state, where the number of people bearing different types of cancer is on the rise, the applications of new and upgraded and conventional forms of radiotherapy are enormous. The supreme urgent necessity requiring the development of improved and progressively precise radiation therapy is the requirement to exactly hit only the affected tumor using the radiation beam and avoid harming the surrounding tissue.
An increase in the elderly population, technological innovations in radiotherapy products, rising conferences driving investments in radiotherapy, growing incidence of cancer incidences, and mounting acceptance of radiotherapy devices and procedures will majorly drive the radiotherapy market.
Though the absence of trained personnel to perform the therapy, practiced alternative medicine, its incapability to be used for metastasis state of cancer and side effects associated with the treatment restrained the market growth.
This research report on the APAC Radiotherapy market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Equipment Type:
By Country:
Regionally, the China radiotherapy market is estimated to dominate the Asia-Pacific market during the forecast period due to a large number of the elderly population in the country and is expected to continue its dominance. In addition, better healthcare infrastructure, increasing per capita income, and a rising number of cancer cases in patients are further estimated to accelerate the growth rate of the Chinese market. Moreover, government funds and investments in bringing awareness among the patients also enhance the market.
In India and Japan, the radiotherapy market is expected to have promising CAGR during the forecast period owing to the launch of new oncology radiation therapeutic systems and the existence of a large number of key players. However, the cost of radiotherapy treatment for people suffering from cancer diseases is one major factor hampering the growth.
KEY MARKET PLAYERS:
Nordion Inc., RaySearch Laboratories AB, Ion Beam Applications SA, C. R. Bard Inc., Mevion Medical Systems Inc., Varian Medical Systems Inc., IsoRay Medical Inc., Elekta AB, Accuray Incorporated, and Mitsubishi Electric Corporation are a few of the notable players in the APAC radiotherapy market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 External Beam Radiation Therapy
5.1.1.1 Intensity-Modulated Radiation Therapy (IMRT)
5.1.1.2 Image-Guided Radiation Therapy (IGRT)
5.1.1.3 Tomotherapy
5.1.1.4 Stereotactic Radiosurgery
5.1.1.5 Stereotactic body Radiation Therapy
5.1.1.6 Proton Therapy
5.1.2 Internal Beam Radiation Therapy
5.1.3 Systemic Radiation Therapy
5.2 By Application
5.2.1 Skin & Lip Cancer
5.2.2 Head & Neck Cancer
5.2.3 Breast Cancer
5.2.4 Prostate Cancer
5.2.5 Cervical Cancer
5.2.6 Lung Cancer
5.2.7 Spine Cancer
5.3 By Equipment Type
5.3.1 Linear Accelerators
5.3.2 Radiation Therapy Simulators
5.3.3 Treatment Planning Systems
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Nordion Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 RaySearch Laboratories AB
9.3 Ion Beam Applications SA
9.4 C. R. Bard Inc.
9.5 Mevion Medical Systems Inc.
9.6 Varian Medical Systems Inc.
9.7 IsoRay Medical Inc.
9.8 Elekta AB
9.9 Accuray Incorporated
9.10 Mitsubishi Electric Corporation
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
